Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Short Interest Update

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 86,503 shares, a growth of ∞ from the April 30th total of 0 shares. Based on an average daily trading volume, of 426,652 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the company’s shares are sold short.

Odyssey Therapeutics Stock Performance

Odyssey Therapeutics stock remained flat at $16.96 during midday trading on Tuesday. The company had a trading volume of 127,382 shares, compared to its average volume of 330,139. Odyssey Therapeutics has a 1-year low of $15.35 and a 1-year high of $20.30.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. TD Cowen began coverage on Odyssey Therapeutics in a research note on Tuesday. They set a “buy” rating for the company. Cantor Fitzgerald began coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “overweight” rating for the company. Wedbush initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $30.00 price objective for the company. Oppenheimer initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $40.00 price objective on the stock. Finally, Wall Street Zen raised shares of Odyssey Therapeutics to a “hold” rating in a research note on Saturday, May 16th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $32.00.

Insiders Place Their Bets

In other Odyssey Therapeutics news, Director Shelley Chu bought 11,111 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $18.00 per share, with a total value of $199,998.00. Following the completion of the purchase, the director owned 11,111 shares in the company, valued at approximately $199,998. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Dimension Capital Ii, L.P. purchased 1,111,111 shares of the stock in a transaction on Friday, May 8th. The stock was acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the acquisition, the director directly owned 3,333,516 shares of the company’s stock, valued at approximately $60,003,288. This represents a 50.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 4,183,777 shares of company stock worth $75,319,986 over the last 90 days.